WO2002075274A3 - Methode et trousse pour le suivi des maladies neurodegeneratives - Google Patents

Methode et trousse pour le suivi des maladies neurodegeneratives Download PDF

Info

Publication number
WO2002075274A3
WO2002075274A3 PCT/FR2002/000927 FR0200927W WO02075274A3 WO 2002075274 A3 WO2002075274 A3 WO 2002075274A3 FR 0200927 W FR0200927 W FR 0200927W WO 02075274 A3 WO02075274 A3 WO 02075274A3
Authority
WO
WIPO (PCT)
Prior art keywords
kit
neurodegenerative diseases
following
following neurodegenerative
detection
Prior art date
Application number
PCT/FR2002/000927
Other languages
English (en)
Other versions
WO2002075274A2 (fr
Inventor
Michel Geffard
Original Assignee
Gemac
Michel Geffard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemac, Michel Geffard filed Critical Gemac
Priority to CA002441170A priority Critical patent/CA2441170A1/fr
Priority to JP2002573641A priority patent/JP2004530871A/ja
Priority to US10/471,788 priority patent/US7195881B2/en
Priority to EP02713027A priority patent/EP1399743A2/fr
Publication of WO2002075274A2 publication Critical patent/WO2002075274A2/fr
Priority to NO20034080A priority patent/NO20034080L/no
Publication of WO2002075274A3 publication Critical patent/WO2002075274A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne une méthode pour la détection et le suivi des maladies neurodégénératives, qui consiste à détecter la présence d'anticorps d'isotypie A et/ou M dirigés contre les antigènes associés à ces maladies. L'invention concerne également une trousse pour la mise en oeuvre de cette méthode.
PCT/FR2002/000927 2001-03-16 2002-03-15 Methode et trousse pour le suivi des maladies neurodegeneratives WO2002075274A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002441170A CA2441170A1 (fr) 2001-03-16 2002-03-15 Methode et trousse pour le suivi des maladies neurodegeneratives
JP2002573641A JP2004530871A (ja) 2001-03-16 2002-03-15 神経変性疾患の管理のための方法及びキット
US10/471,788 US7195881B2 (en) 2001-03-16 2002-03-15 Method and kit for following neurodegenerative diseases
EP02713027A EP1399743A2 (fr) 2001-03-16 2002-03-15 Methode et trousse pour le suivi des maladies neurodegeneratives
NO20034080A NO20034080L (no) 2001-03-16 2003-09-15 Fremgangsmåte og sett for deteksjon av neurodegenerative sykdommer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0103592A FR2822238B1 (fr) 2001-03-16 2001-03-16 Methode et trousse pour le suivi des maladies neurodegeneratives
FR01/03592 2001-03-16

Publications (2)

Publication Number Publication Date
WO2002075274A2 WO2002075274A2 (fr) 2002-09-26
WO2002075274A3 true WO2002075274A3 (fr) 2003-12-11

Family

ID=8861210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/000927 WO2002075274A2 (fr) 2001-03-16 2002-03-15 Methode et trousse pour le suivi des maladies neurodegeneratives

Country Status (8)

Country Link
US (1) US7195881B2 (fr)
EP (1) EP1399743A2 (fr)
JP (1) JP2004530871A (fr)
CN (1) CN1511258A (fr)
CA (1) CA2441170A1 (fr)
FR (1) FR2822238B1 (fr)
NO (1) NO20034080L (fr)
WO (1) WO2002075274A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2822238B1 (fr) 2001-03-16 2003-08-29 Gemac Methode et trousse pour le suivi des maladies neurodegeneratives
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
JP4662557B2 (ja) * 2003-06-09 2011-03-30 レドックス−リアクティブ リエイジェンツ リミテッド ライアビリティー カンパニー 酸化還元反応による血漿タンパク質の結合特異性の改変方法
US9557325B2 (en) * 2003-06-09 2017-01-31 Redox-Reactive Reagents Llc Method of altering the binding specificity of proteins by oxidation-reduction reactions
US7892751B2 (en) * 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition
US7840270B2 (en) * 2003-07-23 2010-11-23 Synapse Biomedical, Inc. System and method for conditioning a diaphragm of a patient
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
US7962215B2 (en) 2004-07-23 2011-06-14 Synapse Biomedical, Inc. Ventilatory assist system and methods to improve respiratory function
US9050005B2 (en) 2005-08-25 2015-06-09 Synapse Biomedical, Inc. Method and apparatus for transgastric neurostimulation
KR101439828B1 (ko) * 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
KR20080090408A (ko) * 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
US20080097153A1 (en) * 2006-08-24 2008-04-24 Ignagni Anthony R Method and apparatus for grasping an abdominal wall
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US9079016B2 (en) * 2007-02-05 2015-07-14 Synapse Biomedical, Inc. Removable intramuscular electrode
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US9820671B2 (en) * 2007-05-17 2017-11-21 Synapse Biomedical, Inc. Devices and methods for assessing motor point electromyogram as a biomarker
US8428726B2 (en) 2007-10-30 2013-04-23 Synapse Biomedical, Inc. Device and method of neuromodulation to effect a functionally restorative adaption of the neuromuscular system
WO2009059033A1 (fr) * 2007-10-30 2009-05-07 Synapse Biomedical, Inc. Procédé d'amélioration des apnées du sommeil
WO2011130377A2 (fr) 2010-04-15 2011-10-20 Abbott Laboratories Protéines de liaison à la bêta amyloïde
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
RU2693627C2 (ru) * 2017-11-03 2019-07-03 Общество С Ограниченной Ответственностью "Валента - Интеллект" Комбинации эдаравона для лечения ишемических повреждений мозга
US11471683B2 (en) 2019-01-29 2022-10-18 Synapse Biomedical, Inc. Systems and methods for treating sleep apnea using neuromodulation
FR3094492A1 (fr) * 2019-04-01 2020-10-02 Polyneuros Procédé de détection ou de suivi de l’évolution d’une maladie chronique dégénérative par dosage immunologique
FR3094493A1 (fr) * 2019-04-01 2020-10-02 Polyneuros Procédé de détection ou de suivi de l’évolution d’une maladie chronique auto-immune par dosage immunologique

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0621479A1 (fr) * 1993-04-23 1994-10-26 Anda Biologicals S.A. Procédé de détection et/ou de quantification de différentes classes d'immunoglobulines specifiques d'une pathologie comportant une réponse auto-immunitaire
FR2762602A1 (fr) * 1997-04-28 1998-10-30 Inst Nat Sante Rech Med Moyens pour la detection precoce de pathologies auto-immunes inflammatoires

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2550799B1 (fr) 1983-08-17 1986-02-21 Commissariat Energie Atomique Compose marque par une enzyme, son procede de preparation et son utilisation en enzymoimmunologie
FR2822238B1 (fr) 2001-03-16 2003-08-29 Gemac Methode et trousse pour le suivi des maladies neurodegeneratives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0621479A1 (fr) * 1993-04-23 1994-10-26 Anda Biologicals S.A. Procédé de détection et/ou de quantification de différentes classes d'immunoglobulines specifiques d'une pathologie comportant une réponse auto-immunitaire
FR2762602A1 (fr) * 1997-04-28 1998-10-30 Inst Nat Sante Rech Med Moyens pour la detection precoce de pathologies auto-immunes inflammatoires

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOULLERNE ANNE I ET AL: "Circulating antibodies directed against conjugated fatty acids in sera of patients with multiple sclerosis.", JOURNAL OF NEUROIMMUNOLOGY, vol. 65, no. 1, 1996, pages 75 - 81, XP002052449, ISSN: 0165-5728 *
BOULLERNE ANNE I ET AL: "Indirect evidence for nitric oxide involvement in multiple sclerosis by characterization of circulating antibodies directed against conjugated S-nitrosocysteine.", JOURNAL OF NEUROIMMUNOLOGY, vol. 60, no. 1-2, 1995, pages 117 - 124, XP002052448, ISSN: 0165-5728 *
DAVERAT P ET AL: "IDENTIFICATION AND CHARACTERIZATION OF ANTI-CONJUGATED AZELAIC ACID ANTIBODIES IN MULTIPLE SCLEROSIS", JOURNAL OF NEUROIMMUNOLOGY, vol. 22, no. 2, 1989, pages 129 - 134, XP008000510, ISSN: 0165-5728 *
MANETA-PEYRET L ET AL: "MEMBRANE LABELING OF THE CORTEX OF AGING RATS BY ANTI-FATTY-ACID ANTIBODIES", NEUROSCIENCE LETTERS, vol. 69, no. 2, 1986, pages 121 - 125, XP008000512, ISSN: 0304-3940 *
MANETA-PEYRET L ET AL: "NATURAL SERIC ANTI-FATTY ACID ANTIBODIES IN MULTIPLE SCLEROSIS", NEUROSCIENCE LETTERS, vol. 80, no. 2, 1987, pages 235 - 239, XP008000511, ISSN: 0304-3940 *

Also Published As

Publication number Publication date
CN1511258A (zh) 2004-07-07
NO20034080D0 (no) 2003-09-15
US20040082015A1 (en) 2004-04-29
JP2004530871A (ja) 2004-10-07
FR2822238A1 (fr) 2002-09-20
US7195881B2 (en) 2007-03-27
NO20034080L (no) 2003-11-14
FR2822238B1 (fr) 2003-08-29
EP1399743A2 (fr) 2004-03-24
CA2441170A1 (fr) 2002-09-26
WO2002075274A2 (fr) 2002-09-26

Similar Documents

Publication Publication Date Title
WO2002075274A3 (fr) Methode et trousse pour le suivi des maladies neurodegeneratives
WO2002030986A3 (fr) ANTICORPS HUMANISES ANTI-LT-β-R
AU2001268855A1 (en) Single-domain antigen-binding antibody fragments derived from llama antibodies
WO2005010048A3 (fr) Anticorps de rg1 et utilisation de ceux-ci
WO2001014424A3 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
WO2003030835A3 (fr) Utilisation d'anticorps bispecifiques pour reguler des reponses immunitaires
WO2007022520A3 (fr) Renfort induit par anticorps de reponse immune
WO2004029207A3 (fr) Variants fc optimises et methodes destinees a leur generation
WO2004099249A3 (fr) Variants fc optimises et leurs procedes de generation
WO2003039470A3 (fr) Immunogene polyvalent
WO2004075850A3 (fr) Immunogene polyvalent
WO2003072803A3 (fr) Nanostructures contenant des unites d'assemblage d'anticorps
WO2004092209A3 (fr) Antigenes s-pneumoniae
AU2002340167A1 (en) Anti-hla-dr antibodies and the methods of using thereof
WO2004099242A3 (fr) Antigènes i + ii contre s. agalactiae
WO2005046597A3 (fr) Anticorps de clycoformes de cd44 et utilisations de ceux-ci
EP1818062A3 (fr) Anticorps anti HSP90
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses
WO2002057794A3 (fr) Compositions et procedes permettant la detection d'anticorps anti-ehrlichia canis et ani-ehrlichia chaffeensis
AU2002354009A1 (en) Process for the preparation of secondary and tertiary amino-functional silanes, iminoorganosilanes and/or imidoorganosilanes
AU2002217213A1 (en) Human monoclonal antibody directed against the influenza virus or a fragment thereof
AU2003225976A1 (en) Anti-tnf antibodies, compositions, methods and uses
AU2002368056A1 (en) Novel pla2 enzyme, it's antibody, enzyme inhibitor and use and the preparation methods thereof
WO2002094881A3 (fr) Anticorps monoclonal neutralisant l'activite de la cathepsine b et utilisations associees
AU2002365269A1 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002713027

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002573641

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 028066081

Country of ref document: CN

Ref document number: 2441170

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10471788

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002244818

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002713027

Country of ref document: EP